EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies

Haojian Gan iD, Junling Lin iD, Qiyin Sun, Jiayi Xu iD, Qingjian He iD, Shuo Chen iD, Yu Feng iD, Bicheng Hu iD, Wenjuan Wang iD

Reviews in Cardiovascular Medicine · 26.06.2026 · 27 (6)

DOI: 10.31083/rcm47740 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 26.06.2026. Verfasst von Haojian Gan und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Huzhou Science and Technology Bureau Public Welfare Application Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton's tyrosine kinase (BTK) inhibitors are important targeted drugs for treating chronic B-cell malignancies, and have played a key role in improving patient prognosis and treatment efficacy. However, despite the significant advantages of BTK inhibitors in anti-tumor therapy, the use of these drugs also promotes certain cardiovascular risks, including atrial fibrillation (AF), bleeding, hypertension, heart failure, and potential ventricular arrhythmias (VAs). The latest generation of BTK inhibitors has shown progress in reducing the incidence of these adverse events; however, cardiovascular adverse events (CVAEs) cannot be ignored and continue to pose challenges to patient safety. Therefore, determining how to optimize the clinical application of Bruton’s tyrosine kinase inhibitor (BTKi) further has become an urgent problem. This review systematically analyzes the pathogenesis and clinical manifestations of BTK inhibitor-related cardiovascular complications, with a particular focus on the epidemiological characteristics and potential risk factors of common adverse reactions, such as hypertension, AF, bleeding, and stroke. Moreover, this review explores the pathological and physiological mechanisms, further evaluates the effectiveness of current risk management and intervention strategies, and proposes future research to elucidate mechanisms, optimize doses, and explore combination therapy. Meanwhile, through in-depth analysis and comprehensive evaluation of existing data, this review aims to provide a more scientific basis for clinical decision-making, while promoting research into the safety of continuous BTK inhibitor use to achieve improved treatment outcomes while balancing efficacy and safety.

Schlagwörter

Stichwörter der Autor:innen

Bruton's tyrosine kinase inhibitorsatrial fibrillationcardiovascular adverse eventsdrug-related hypertensionhemorrhagic complicationsischemic and hemorrhagic stroke

Autor:innen und Institutionen

  • School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China.
  • Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China.
  • Department of Breast and Thyroid Surgery, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China.

ORCID-Profile: Haojian Gan, Junling Lin, Jiayi Xu, Qingjian He, Shuo Chen, Yu Feng, Bicheng Hu, Wenjuan Wang

Förderung

  • Huzhou Science and Technology Bureau Public Welfare Application Research Project

Zitieren

APA

Gan, H., Lin, J., Sun, Q., Xu, J., He, Q., Chen, S., Feng, Y., Hu, B., & Wang, W. (2026). Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies. Reviews in Cardiovascular Medicine, 27(6). https://doi.org/10.31083/rcm47740

Vancouver

Gan H, Lin J, Sun Q, Xu J, He Q, Chen S, et al. Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies. Reviews in Cardiovascular Medicine. 2026;27(6). doi:10.31083/rcm47740

BibTeX
@article{Gan2026,
  author = {Gan, Haojian and Lin, Junling and Sun, Qiyin and Xu, Jiayi and He, Qingjian and Chen, Shuo and Feng, Yu and Hu, Bicheng and Wang, Wenjuan},
  title = {Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2026},
  volume = {27},
  number = {6},
  doi = {10.31083/rcm47740}
}
Kostenlos starten →